Opinion|Videos|October 13, 2023
Available Treatment Options for Patients with Advanced RCC
Author(s)Robert J. Motzer, MD, Elizabeth Plimack, MD
Medical oncologists discuss a patient's surprising rapid decline after an initial diagnosis of clear cell RCC, emphasizing the efficacy of combination lenvatinib/pembrolizumab in similar patients.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA approved iberdomide plus daratumumab and dexamethasone for relapsed/refractory multiple myeloma.
Sara Nunnery, MD, MSCI, and Kelly E. McCann, MD, PhD, discuss practice-changing data with T-DXd for HER2-positive breast cancer.
A UCLA study found that traditional pathological features do not predict who will benefit more from adding hormone therapy to postoperative radiation.
Zipalertinib plus chemotherapy produced a statistically significant, clinically meaningful PFS improvement vs chemotherapy alone at a planned interim analysis.
Pooled results from the phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials confirmed the efficacy of pirtobrutinib in treatment-naive CLL.
Michael J. Morris, MD, discusses the FDA approval of lutetium Lu 177 vipivotide tetraxetan plus an ARPI in PSMA+ mHSPC.
Neoadjuvant PD-1–based immunotherapy plus chemotherapy produced pCRs across three cohorts in resectable locally advanced HNSCC.
A post hoc analysis found similar safety outcomes for fixed-duration regimens containing acalabrutinib/venetoclax across age groups in treatment-naive CLL.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
Dr Banerjee on the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
3
Dr Carlino on 5-Year Data With Intismeran Plus Pembrolizumab in Resected Melanoma
4
Dr Garg on a Phase 3 Study of Proton Therapy in Head and Neck Cancer
5